TABLE 4.
Group (n) | Simultaneous use of an aminoglycoside for ≥3 days (n) | No. (%) of patients with severe complications |
---|---|---|
Cefazolin (59) | Yes (50) | 17 (34.0) |
No (9) | 5 (55.6) | |
Extended-spectrum cephalosporin (48) | Yes (21) | 2 (9.5) |
No (27) | 1 (3.7) |
The P value for the difference between rates of developing severe complications depending on whether aminoglycosides were used for ≥3 days or <3 days was 0.774. The Mantel-Haenszel common odds ratio for development of severe complications in patients treated with aminoglycosides for ≥3 days was 0.7 (95% CI: 0.2 to 2.3).